Revenues slip, loss posted in Draxis' Q1

Lower sales of sterile products, the negative impact of a stronger Canadian dollar, and costs related to the potential sale of the company combined to stymie growth at Draxis Health in the first quarter (end-March 31).

Consolidated revenues for the Montreal-based company slipped 8% to $19.2 million (U.S.), compared with $21 million in the first quarter of 2007. Product sales declined to $18.7 million, down 5% from $19.6 million in the first quarter of 2007.

The firm's first-quarter net loss was $1.4 million, compared with a net income of $2 million in the same quarter a year ago.

On April 4, Draxis reached an agreement for Jubilant Organosys of Noida, India, to acquire all of Draxis' outstanding common shares for $255 million. The transaction is pending.

Related Reading

Indian firm to buy Draxis for $255 million, April 4, 2008

Draxis confirms sell-off rumors, March 17, 2008

Chalk River shutdown hurts Draxis' results, February 8, 2008

Draxis previews Q4 earnings, January 18, 2008

Draxis Health names new leaders, January 8, 2008

Copyright © 2008

Page 1 of 436
Next Page